StartsideHDP1 • FRA
add
Arrowhead Pharmaceuticals Inc
Forrige sluttkurs
25,85 €
Dagsintervall
25,67 € - 25,67 €
Årsintervall
19,52 € - 36,69 €
Markedsverdi
3,58 mrd. USD
P/E-tall
-
Utbytte
-
Hovedbørs
NASDAQ
I nyhetene
Økonomi
Resultatregnskap
Omsetning
Nettoomsetning
(USD) | mars 2024info | Endring år til år |
---|---|---|
Omsetning | — | — |
Driftskostnader | 126,19 mill. | 28,63 % |
Nettoomsetning | −125,30 mill. | −357,42 % |
Netto resultatmargin | — | — |
Fortjeneste per aksje | −1,02 | −326,67 % |
EBITDA | −121,67 mill. | −339,34 % |
Faktisk avgiftssats | — | — |
Balanseregnskap
Totale aktiva
Totale passiva
(USD) | mars 2024info | Endring år til år |
---|---|---|
Kontant / kortsiktige inv. | 520,91 mill. | 8,30 % |
Totale aktiva | 955,15 mill. | 7,16 % |
Totale passiva | 459,74 mill. | 7,87 % |
Total egenkapital | 495,40 mill. | — |
Utestående aksjer | 124,20 mill. | — |
P/B-forhold | 6,63 | — |
Avkastning på aktiva | −39,90 % | — |
Avkastning på kapital | −43,18 % | — |
Kontantstrøm
Netto kontantstrøm
(USD) | mars 2024info | Endring år til år |
---|---|---|
Nettoomsetning | −125,30 mill. | −357,42 % |
Kontantstrøm fra drift | −92,38 mill. | −191,68 % |
Kontanter fra investering | −268,94 mill. | −645,70 % |
Kontanter fra finansiering | 430,78 mill. | 82 741,73 % |
Netto kontantstrøm | 69,49 mill. | 203,27 % |
Fri kontantstrøm | −91,82 mill. | −262,49 % |
Om
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease. The company has sixteen products in its pipeline, in various stages of development.
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.
In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.
In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. Wikipedia
Administrerende direktør
Grunnlagt
1. jan. 2004
Hovedkvarter
Nettsted
Ansatte
525